Actually, Matoba et al. discovered that Treg cells expressing abundant CTLA-4 on the cell surface were expanded in human HNSCC samples and suggested it as a new therapeutic target to evoke effective immune responses to HNSCC [105]. Here, CTLA4 is linked to head and neck squamous cell carcinoma.